Nuvation Bio Acquires Exclusive Rights to Safusitinib in Japan From Daiichi Sankyo

Why It Matters

The shift to first‑line use and durable responses positions Iptrozy for revenue stacking and long‑term growth, while strong cash and partnership cash flow give Nuvation a runway to advance its pipeline.

Key Takeaways

• Iptrozy Q1 revenue $18.5M, 18% QoQ growth.
• Over 50% new starts are TKI‑naive first‑line patients.
• Collaboration revenue $64.7M, including $60M Eisai upfront.
• Cash balance $534M, no external financing needed.
• Safusitinib Japan rights secured, expanding SIGMA trial.

Pulse Analysis

The oncology market for ROS1‑positive non‑small cell lung cancer remains niche, but Nuvation Bio’s Iptrozy is rapidly gaining traction as a preferred first‑line option. By the end of Q1, more than 50 % of new patients were TKI‑naive, a clear sign that physicians are moving the drug earlier in the treatment algorithm. This shift is reinforced by a 97 % aided awareness among target oncologists and full adoption across the top 50 historical TKI accounts. Longer median duration of response—now around 50 months—translates into a larger, more durable patient pool, setting the stage for sustained revenue stacking.

Financially, the quarter highlighted the power of Nuvation’s partnership model. Collaboration and license revenue contributed $64.7 million, anchored by an almost $60 million upfront payment from Eisai for European development. Product sales added $18.5 million, while operating expenses of $73.5 million reflected continued investment in the SIGMA and TRUST programs. Despite a modest rise in gross‑to‑net discounts, the company closed the period with $533.7 million in cash and marketable securities, eliminating the need for near‑term external financing and preserving flexibility for future R&D spend.

Beyond Iptrozy, Nuvation is expanding its pipeline with safusitinib, a targeted therapy for IDH1‑mutant glioma. The acquisition of exclusive Japanese rights from Daiichi Sankyo enables the SIGMA Phase 3 trial to enroll in a key market and strengthens global control of the program. Early‑stage data suggest activity across all four glioma sub‑populations, positioning safusitinib as a potential first‑in‑class option. With patient‑reported outcomes from the TRUST program and TRUST‑4 results slated for ASCO, the company is building a robust data franchise that could drive further commercial upside and diversify revenue streams.

Deal Summary

Nuvation Bio announced that it has completed the acquisition of exclusive rights to the IDH1‑mutant glioma drug safusitinib in Japan from partner Daiichi Sankyo. The agreement, finalized in April 2026, expands Nuvation’s portfolio and enables the company to advance the SIGMA trial in the Japanese market. The deal was disclosed during the company’s Q1 2026 earnings call.